Universal Ibogaine Inc. reported earnings results for the third quarter and nine months ended April 30, 2022. For the third quarter, the company reported sales was CAD 0.369123 million. Net loss was CAD 1.17 million compared to CAD 1.05 million a year ago.
For the nine months, sales was CAD 0.939604 million. Net loss was CAD 3.94 million compared to CAD 2.69 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.03 a year ago.